---
title: "Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Economic burden and healthcare resource utilization"
description: "Formulary evidence on Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Economic burden and healthcare resource utilization. Topics: Annual direct medical costs of NAFLD in the United States, steady-state prevalence model; Lifetime direct costs of NASH and advanced NASH in US adults, Markov model, 2017; Direct medical and indirect costs by early (F0 to F2) and advanced (F3 to F4) fibrosis in adults with NASH, United States and five European countries, GAIN study, 2018; Annual non-drug costs by fibrosis stage and liver health state in a US cost-effectiveness model, based on US estimates from the GAIN study; 9 further topics. 13 evidence topics quoted from 13 sources."
canonical: "https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/product-information-and-disease-description/economic-burden-and-healthcare-resource-utilization"
published: "2026-11-18T22:34:49-05:00"
modified: "2026-11-18T22:34:49-05:00"
---

# Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Economic burden and healthcare resource utilization

<a id="heading-2.2.1.8.2"></a>

## 2.2.1.8.2 Economic Burden and Healthcare Resource Utilization

<a id="topic-2.2.1.8.2-1"></a>

### Annual direct medical costs of NAFLD in the United States, steady-state prevalence model

> “We constructed a steady-state prevalence model to quantify this burden in the United States and Europe.”
> “In the United States, over 64 million people are projected to have NAFLD, with annual direct medical costs of about $103 billion ($1,613 per patient).”
> “Costs are highest in patients aged 45-65. The burden is significantly higher when societal costs are included.”

Source: [Younossi et al. (2016b)](https://pubmed.ncbi.nlm.nih.gov/27543837/)

<a id="topic-2.2.1.8.2-2"></a>

### Lifetime direct costs of NASH and advanced NASH in US adults, Markov model, 2017

> “We constructed lifetime Markov models for all stages of NASH and a separate model to specifically identify the increased burden of advanced NASH (fibrosis stage >3).”
> “Costs included inpatient, outpatient, professional services, emergency department, and drug costs, which were obtained from the Center for Medicare and Medicaid Services Fee Schedule 2017 and published data.”
> “Lifetime costs of all NASH patients in the United States in 2017 will be $222.6 billion, and the cost of the advanced NASH population will be $95.4 billion.”

Source: [Younossi et al. (2019a)](https://pubmed.ncbi.nlm.nih.gov/30180285/)

<a id="topic-2.2.1.8.2-3"></a>

### Direct medical and indirect costs by early (F0 to F2) and advanced (F3 to F4) fibrosis in adults with NASH, United States and five European countries, GAIN study, 2018

> “In total, 3,754 patients found to have NASH on liver biopsy were stratified by fibrosis score and by biomarkers as either early or advanced fibrosis.”
> “All patients were categorised as having early (F0–F2) or advanced (F3–F4) fibrosis stage.”
> “For 2018, the mean total annual per patient cost of NASH was €2,763, €4,917, and €5,509 for direct medical, direct non-medical, and indirect costs, respectively. National per-patient cost was highest in the USA and lowest in France. Costs increased with fibrosis and decompensation, driven by hospitalisation and comorbidities. Indirect costs were driven by work loss.”
> “Overall, costs for patients with advanced fibrosis were higher (€3,983) than for those with early-stage fibrosis (€2,224).”
> “A major share of indirect costs resulted from early retirement or stopping working (74%), followed by time off work in the previous 12 months (26%).”
> “Patient indirect or productivity-related costs correlated positively with NASH severity, because patients with relatively more severe disease had to stop working (12% vs. 5% in patients with early-stage disease) or cited that their retirement was the result of NASH (13% vs. 5% in patients with early-stage disease)”

Source: [O'Hara et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7397699/)

| Mean annual cost per patient (SD) | Early fibrosis | Advanced fibrosis | USA |
| --- | --- | --- | --- |
| NASH-related direct medical (physician-reported, n = 2,604, 1,150, 1,221) | “€2,224 (19,956)” | “€3,983 (23,788)” | “€4,881 (42,077)” |
| Total direct medical, NASH-related and non-NASH | “€3,883 (20,634)” | “€6,727 (25,052)” | “€7,258 (36,704)” |
| Indirect (patient-reported, n = 546, 221, 97) | “€5,939 (15,989)” | “€12,642 (21,813)” | “€13,435 (29,493)” |

Source: [O'Hara et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7397699/)

<a id="topic-2.2.1.8.2-4"></a>

### Annual non-drug costs by fibrosis stage and liver health state in a US cost-effectiveness model, based on US estimates from the GAIN study

> “We used NASH-specific costs for early and advanced fibrosis based on the US estimates from the GAIN study where direct medical resource utilization information was collected on web-based case record forms by specialists. These estimates were then adjusted to an annual time period.”

Source: [ICER Final Evidence Report, resmetirom and obeticholic acid for NASH (2023)](https://icer.org/wp-content/uploads/2025/01/NASH-Final-Report_Updated_011025.pdf)

| Health state | Annual cost, base case | Lower value | Upper value |
| --- | --- | --- | --- |
| F0 to F2 | “$7,063” | “$5,650” | “$8,475” |
| F3 | “$8,423” | “$6,738” | “$10,108” |
| Compensated cirrhosis | “$34,275” | “$27,420” | “$41,131” |
| Decompensated cirrhosis | “$158,480” | “$126,784” | “$190,176” |
| Hepatocellular carcinoma | “$115,002” | “$92,001” | “$138,002” |

Source: [ICER Final Evidence Report, resmetirom and obeticholic acid for NASH (2023)](https://icer.org/wp-content/uploads/2025/01/NASH-Final-Report_Updated_011025.pdf)

<a id="topic-2.2.1.8.2-5"></a>

### Annual direct medical cost by liver health state, 2025 US dollars, payer-perspective model funded by a diagnostics manufacturer

> “Our study was conducted from a health-care payer perspective and included direct medical costs associated with each health state (Table 2), including inpatient and outpatient, medications, and procedures.”
> “All costs were sourced from published literature using a combination of micro-costing and gross-costing methods, adjusted using the Consumer Price Index, and reported in 2025 United States dollars.”
> “This study was funded by Siemens Healthcare Diagnostics Inc, Tarrytown, NY, USA who contributed to conceptualization, design, data collection, analysis, decision to publish, and preparation of the article.”

Source: [Chen et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13087396/)

| Health state | Direct medical cost, 2025 USD per year, base value | Range |
| --- | --- | --- |
| F0-1 | “500” | “480–510” |
| F2-3 | “1180” | “640–1720” |
| Compensated cirrhosis | “23,360” | “18,210–28,510” |
| Decompensated cirrhosis | “36,290” | “30,190–42,390” |
| Hepatocellular carcinoma | “85,840” | “60,900–110,790” |

Source: [Chen et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13087396/)

<a id="topic-2.2.1.8.2-6"></a>

### All-cause annual costs by FIB-4 category in 6,743 US adults with NASH, linked electronic health record and claims data, 2016 to 2020

> “Adults with NASH were identified in the Veradigm Health Insights Electronic Health Record Database and linked Komodo claims data. The index date was the earliest coded NASH diagnosis between 1 January 2016 and 31 December 2020 with valid FIB-4 and ≥6 months of database activity and continuous enrollment pre- and post-index.”
> “Among 6,743 qualifying patients, index FIB-4 was ≤0.95 for 2,345 patents, 0.95-2.67 for 3,289 patients, 2.67-4.12 for 571 patients, and >4.12 for 538 patients (mean age 55.8 years; 62.9% female).”
> “Mean age, comorbidity burden, cardiovascular disease risk, and healthcare utilization increased with increasing FIB-4. Mean ± SD annual costs increased from $16,744±$53,810 to $34,667±$67,691 between the lowest and highest FIB-4 cohorts”
> “A one-unit increase in FIB-4 at index was associated with a 3.4% (95%CI: 1.7%-5.2%) increase in mean total annual cost and an 11.6% (95%CI: 8.0%-15.3%) increased likelihood of hospitalization.”

Source: [Tapper et al. (2023a)](https://pubmed.ncbi.nlm.nih.gov/36866575/)

<a id="topic-2.2.1.8.2-7"></a>

### Health care costs after identification of FIB-4-defined F3 or F4 fibrosis in 251,725 commercially insured US adults with NAFLD or NASH, 2008 to 2016

> “Using the Optum Research Database, a retrospective cohort study was conducted among 251,725 commercially insured adult patients with ≥1 NAFLD/NASH diagnosis from January 1, 2008, to August 31, 2016, and laboratory data required to calculate FIB‐4 scores.”
> “The prevalence of FIB‐4‐based F3 and F4 fibrosis was 0.40%‐2.72% and 1.03%‐1.61%, respectively. Almost 50% of patients identified with FIB‐4‐based F3 or F4 had type 2 diabetes, cardiovascular disease, or renal impairment.”
> “Total all‐cause health care costs increased significantly from pre‐index to post‐index for patients with FIB‐4‐based F3 fibrosis across most criteria (17%‐29% increase) and patients with FIB‐4‐based F4 fibrosis across all criteria (47%‐48% increase). Inpatient costs were the primary drivers of this increment.”

Source: [Gordon et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7327220/)

<a id="topic-2.2.1.8.2-8"></a>

### Annual all-cause costs by advanced liver disease stage in 485,774 commercially insured US adults with NAFLD or NASH, 2016 US dollars

> “Adult NAFLD/NASH patients were identified retrospectively from MarketScan Commercial claims (2006-2016). Following initial NAFLD/NASH diagnosis, advanced liver diseases were identified using the first diagnosis as their index date. Mean annual all-cause HRU and costs (2016 USD) were reported.”
> “Within the database, 485,774 NAFLD/NASH patients met eligibility criteria.”
> “Compared with NAFLD/NASH without advanced liver diseases (adjusted costs: $23,860), the annual cost of CC, DCC, LT, and HCC were 1.22, 5.64, 8.27, and 4.09 times higher [adjusted costs: $29,078, $134,448, $197,392, and $97,563 (P<0.0001)]. Inpatient admissions significantly drove increasing HRU.”

Source: [Wong et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8500367/)

<a id="topic-2.2.1.8.2-9"></a>

### Inpatient and outpatient charges and payments in Medicare beneficiaries with NAFLD, with and without cirrhosis, 2010

> “Medicare beneficiaries (January 1, 2010 to December 31, 2010) with NAFLD diagnosis by International Classification of Diseases, Ninth Revision codes in the absence of other liver diseases were selected.”
> “A total of 976 inpatients and 4742 outpatients with NAFLD were included—87% were white, 36% male, 30% had cardiovascular disease (CVD) or metabolic syndrome conditions, and 12% had cirrhosis.”
> “For inpatients, median total hospital charge was $36,289. NAFLD patients with cirrhosis had higher charges and payments than noncirrhotic NAFLD patients ($61,151 vs. $33,863 and $18,804 vs. $10,146, P<0.001).”
> “For outpatients, median total charge was $9,011. NAFLD patients with cirrhosis had higher charges and payments than noncirrhotic NAFLD patients ($12,049 vs. $8,830 and $2,586 vs. $1,734, P<0.001).”

Source: [Sayiner et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5300028/)

<a id="topic-2.2.1.8.2-10"></a>

### Health care resource use and work impairment in 136 US adults with NASH versus matched general population, 2016 National Health and Wellness Survey

> “Data came from the 2016 National Health and Wellness Survey, a nationally representative patient-reported outcomes survey conducted in the United States.”
> “After adjusting for baseline demographics and characteristics, NASH (N = 136) compared to the matched general population cohort (N = 544)”
> “In terms of HRU, there were more visits to an HCP (8.43 vs. 5.17, p < 0.001), ER visits (0.73 vs. 0.38, p = 0.021), and hospitalizations (0.43 vs. 0.21, p = 0.024) for NASH compared to the matched general population cohort (Fig. 3) and NASH patients reported more specialty visits (p’s < 0.05), for example, more general/family medicine provider visits (1.49 vs. 1.14, p = 0.040), hepatologist visits (0.10 vs. 0.02, p = 0.022), and gastroenterologist visits (0.38 vs. 0.12 p < 0.001)”
> “Impairment of work and activity on WPAI was significantly higher for NASH patients compared to matched general population cohort, including absenteeism (17.0% vs. 9.2%, p = 0.041) and presenteeism (32.9% vs. 22.2%, p = 0.019), as well as overall work impairment (39.6% vs. 26.2%, p = 0.011), and activity impairment (44.7% vs. 30.8%, p < 0.001)”

Source: [Tapper et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10077759/)

<a id="topic-2.2.1.8.2-11"></a>

### Work productivity and activity impairment by fibrosis risk category in 429 US adults with MASH, 2019 and 2022 physician and patient surveys

> “We assessed work productivity burden in a real-world population with suspected/confirmed MASH, comparing work productivity and symptoms across subgroups (risk status, age, BMI, and comorbidities) in the USA using secondary data from Adelphi Real World MASH Disease Specific Programmes™, cross-sectional surveys of physicians and consulting patients in 2019 and 2022.”
> “These risk categories were: low-risk MASH (liver biopsy fibrosis stages F0–2, VCTE <8.0 kPa; FIB-4 <1.3); indeterminate (liver biopsy n/a, VCTE >8.0–12.0 kPa; FIB-4 n/a); and high-risk MASH (liver biopsy fibrosis stages F3–4, VCTE >12 kPa; FIB-4 ≥1.3).”
> “In total, 87 physicians and 429 individuals with MASH provided data. The impact of MASH on activities was greater in high-versus low-risk MASH (activity impairment score: high risk, 30.8%; low risk, 17%; p <0.001 across all risk categories). Overall work impairment scores were 18.8% in low-risk and 19.9% in high-risk MASH.”
> “This analysis was funded by Eli Lilly and Company.”

Source: [Shinde et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12519272/)

<a id="topic-2.2.1.8.2-12"></a>

### Hospitalization and work impairment by fibrosis stage in adults with MASH, Canada, France, Germany, and Italy, 2024

> “Data were drawn from the Adelphi Real World MASH Disease Specific Programme™, a cross-sectional survey of physicians and patients with MASH in Canada, France, Germany, and Italy between January 2024 and June 2024.”
> “AFwC patients also experienced greater impairment while working compared with EFnoC patients (29.7 ± 26.5 [n = 35] vs. 16.1 ± 21.3 [n = 28], p = 0.0271).”
> “On average, the overall hospitalization rate was low in the 12 months before data collection (mean: 0.1 ± 1.1 times). However, those with AFwC were significantly more likely to be hospitalized because MASH comorbidities compared with those with EFnoC (p <0.0001; Table S7).”

Source: [Marquardt et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13019595/)

<a id="topic-2.2.1.8.2-13"></a>

### Modeled US health care costs averted by a hypothetical therapy halting fibrosis progression in MASLD with moderate to advanced fibrosis

> “The US MASLD disease burden model is a Markov model which forecasts disease progression and the impact of diagnosis and treatment. Diagnostic costs for all patients and direct costs for patients with MASLD-related liver disease were also incorporated.”
> “The scenarios in which a hypothetical therapy halts fibrosis progression resulted in reductions in cases of decompensated cirrhosis (11-39%), hepatocellular carcinoma (10-34%), and liver-related deaths (8-31%), a 9-31% reduction in cumulative DALYs, and $40.5 to $99.1B incremental healthcare costs averted.”
> “Increasing diagnosis and treatment for the MASLD population with moderate-to-advanced fibrosis will prevent advanced liver disease and death and will result in reducing the associated direct healthcare costs.”

Source: [Wallace et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39832655/)

## Related pages
- [Lanifibranor (IVA337): Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Terms and abbreviations](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/terms-and-abbreviations.md)
- [Lanifibranor (IVA337): Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/executive-summary.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Product information and disease description](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/product-information-and-disease-description.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Clinical evidence](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/clinical-evidence.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Economic information and modeling report](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/economics) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/economics.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: References](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/references) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/references.md)
